Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (April 2015)
28 slides from Relmada Therapeutics's investor presentation, Apr 23, 2015
Slide 1: Relmada Therapeutics: Innovations in Pain Medicine
RELMADA THERAPEUTICS Innovations in Pain Medicine™ April 2015 Ticker Symbol OTCQB:RLMD
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or in other documents of Relmada Therapeutics (the “Company” certain statements that may be made by management of the Company orally in presenting this material, may contain “forward. looking statements.” These statements c
Slide 3: Company Highlights
RELMADA Company Highlights Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain Three products combine proven drug candidates with novel delivery methods to create new drugs with new indications, while the
Slide 4: Experienced Senior Management
RELMADA Experienced Senior Management An impressive track record developing successful drugs Sergio Traversa, PharmD Chief Executive Officer Eli Lilly, Johnson & Johnson, ING Barings, Mehta & Isaly, Meriin BioMed, Rx Capital Eliseo Salinas, M.D., M.Sc. President & CSO Shite, Elan, Adolor, Wyeth Doug
Slide 5: Scientific Advisors
Scientific Advisors Internationally recognized expertise from world-class scientific advisors Cancer Center. London weoteime (8) Memorial Sloan Kettering Imperial College a JOHNS HOPKINS Gavril Pasternak, MD, PhD Andrew Rice, MD, FRCA Eric ¢. Strain, MD Char Neurology Research at mpera B ROCHESTER R
Slide 6: Pain: Largest U.S. Public Health Crisis
et RELMADA Pain: Largest U.S. Public Health Crisis Prevalence 100M: Persistent Pain Annual Healthcare & Productivity Cost: $560-630 Billion’ 80M? | cardiovascular Disease 334 Million Aanua Heathere& Product Prescriptions and $13 Billion 29M2 cancer Annual Healthcare & Productivity in Sales® Cost. $1
Slide 7: Portfolio Covers Entire Chronic Pain Spectrum
ee? RELMADA Portfolio Covers Entire Chronic Pain Spectrum Products in Market 2013 Sales ($M) Relmada Product Candidates. Kadian®* Avinza® Severe Opanae* Nucynta OxyContin® Vicodin&* Ultram@* Moderate Bulanes) d-Methadone Suboxone® REL-1017 MepiGel Gabapentino* REL-1021
Slide 8: Robust Product Portfolio
et RELMADA Robust Product Portfolio Significant value creation possible in 12-24 months due to accelerated development timelines Pre-clinical Phase 1 Phase 2 Phase 3 d-Methadone REL-1017 ddojeneq LevoCap ER REL-1015 Wed Aloje;nBar (z)(q)¢0g MepiGel Topical gel dosage form of local anesthetic REL-102
Slide 9: d-Methadone
d-Methadone Novel NMDA antagonist for the treatment of neuropathic pain a. 4 RELMAD
Slide 10: d-Methadone - Benefits, Advantages, Features
et RELMADA d-Methadone - Benefits, Advantages, Features Neuropathic pain represents a large market opportunity ready for a new effective entry * d-Methadone is a novel drug — Noncompetitive N-methyl-D-aspartate (NMDA) antagonist — Potential new treatment for estimated 5 million people suffering from
Slide 11: d-Methadone - Proof of Concept
SSS et RELMADA d-Methadone — Proof of Concept * Upregulation of NMDA plays important role in neuropathic pain * Inhibition of NMDA produces strong analgesia in neuropathic pain states — Example: low dose ketamine’ — Severe side effects limit use of ketamine + Psychedelic symptoms (hallucinations, me
Slide 12: d-Methadone Next Steps
SSS et RELMADA d-Methadone Next Steps Multiple development milestone potential in next 12-24 months H1 2015 2016 + Complete Phase | : + Complete Phase | multi dose study in at Dey n single dose study in ~20 patients Rey ae Phase II ~56 patients + FDA meeting PY z interim results + Human pain model 2
Slide 13: LevoCap ER
LevoCap ER Extended release, abuse resistant form of broad spectrum opioid levorphanol RELMADA
Slide 14: LevoCap ER - Benefits, Advantages, Features
SSS et RELMADA LevoCap ER - Benefits, Advantages, Features LevoCap ER will compete in the $8.5 billion opioid market if approved * LevoCap ER is an extended release, abuse deterrent formulation of levorphanol * Levorphanol is a unique, broad spectrum opioid with additional “non-opioid” mechanisms of
Slide 15: Levorphanol's Broad Spectrum Activity
et RELMADA Levorphanol’s Broad Spectrum Activity Levorphano!'s multi-modal mechanism of action provides for a more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Non-Opioid Mechanism Traditional Mu Opioid Receptors Seroto! Med hell i
Slide 16: LevoCap ER Next Steps
RELMADA LevoCap ER Next Steps Multiple development milestone potential in next 12-24 months H1 2015 a * Obtain regulatory FDA end of Phase approval from Il meeting + Continue Phase 3 Health Canada to start clinical trial * StartPhase ll * Pending feedback from FDA meeting 16
Slide 17: BuTab ER
BuTab ER First oral tablet form of buprenorphine for treating both pain and addiction
Slide 18: BuTab ER - Benefits, Advantages, Features
RELMADA BuTab ER - Benefits, Advantages, Features The first form of buprenorphine in a tablet for use in pain and treating addiction Buprenorphine is a partial opioid agonist with two indications: addiction and pain — More than $1.6 billion in annual revenue — Only schedule III opioid under Controll
Slide 19: BuTab ER - Proof of Concept
RELMADA BuTab ER - Proof of Concept 1. Positive single dose bioavailability of oral buprenorphine demonstrated in dogs 2. Inhibition of CYP3A4 enzyme with steroid budesonide — Poor oral drug bioavailability due to cytochrome P450 (CYP)- mediated first-pass metabolism + Sub-family enzyme CYP3A4 is re
Slide 20: BuTab ER Next Steps
SSS et RELMADA BuTab ER Next Steps Multiple development milestone potential in next 12-24 H1 2015 ¥ Obtain regulatory approval from Health Canada to start clinical trial + Start Phase 1 in ~30 patients months H2 20 Complete proof-of- concept Phase | 2016 NDA filing for opioid dependence Start Phase
Slide 21: MepiGel
MepiGel Topical gel dosage form of the local anesthetic mepivacaine for the treatment of neuropathic pain RELMADA
Slide 22: MepiGel - Benefits, Advantages, Features
RELMADA MepiGel - Benefits, Advantages, Features MepiGel will compete with Lidoderm® patch and its $948 million in peak sales if approved « MepiGel is the first topical gel dosage form of local anesthetic mepivacaine, which has intrinsic vasoconstrictor attributes — Reduces rate at which drug is cle
Slide 23: MepiGel Next Steps
RELMADA MepiGel Next Steps Multiple development milestone potential in next 12-24 months H1 20 H2 2015 2016 + Human pain model * File Clinical Trial * Complete Phase! + Proof-of-concept Application (CTA) in ~20 patients Phase II in +200 patients 2
Slide 24: Milestones & Commercial Opportunity
MILESTONES & COMMERCIAL OPPORTUNITY RELMADA
Slide 25: Near-term Value Drivers
Near-term Value Drivers Multiple development milestone potential in next 12-24 months + Complete Phase! muti GCEturtl yim - Complete Phasel single dose study e nee then REL-1017 dose study + FDAmeeting iene + Human pain model results + FDAend of Phase ll Teer 1=549) * Obtain regulatory approval meet
Slide 26: Commercial Opportunity
ee? RELMADA Commercial Opportunity Multi-billion established markets for chronic pain therapy Products in Market 2013 Sales ($M) Relmada Product Candidates. Kadian®* Avinza® Severe Opanae™ Nucynta OxyContin® Vicodin&* A REL-1028 @ REL-1015 Ultram@* Suboxone® REL-1017 Moderate eunianes d-Methadone Ly
Slide 27: Company Highlights
RELMADA Company Highlights Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain Three products combine proven drug candidates with novel delivery methods to create new drugs with new indications, while the
Slide 28: Relmada Therapeutics contact details
RELMADA THERAPEUTICS Innovations in Pain Medicine™ 546 Fifth Ave 14th Floor New York, NY 10036 www.relmada.com Tel: (212) 702-7163 Email: [email protected] Ticker Symbol OTCQB:RLMD
Relmada Therapeutics — Investor Presentation (April 2015) on 6ix